• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Retinoblastoma dr vandana
 

Retinoblastoma dr vandana

on

  • 1,885 views

Presented by Dr. Vandana

Presented by Dr. Vandana
CSMMU, Lucknow
Earlier King George Medical University.

Statistics

Views

Total Views
1,885
Views on SlideShare
1,883
Embed Views
2

Actions

Likes
2
Downloads
176
Comments
0

2 Embeds 2

http://www.linkedin.com 1
http://www.slashdocs.com 1

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment
  • The normal retina extends from the posterior “pole” forward to a region just behind the lens, in cross-section called the ora serrata . The anterior chamber of the eye is between the cornea and the iris; the posterior chamber is just behind it, between the iris and the lens.Behind the lens is the vitreous chamber, with vitreous humor, a thick clear gel-like substance. In advanced retinoblastoma, “seeding” of the tumor is noted in this chamber.
  • The Reese- Ellsworth classification, still the most widely used retinoblastoma organization system, is based on intraocular tumor staging and globe salvage prediction after EBRT; survival is not taken into account in this categorization.

Retinoblastoma dr vandana Retinoblastoma dr vandana Presentation Transcript

  • Presented By:Dr. VandanaDept. of RadiotherapyCSMMU
  • Clinical Anatomy The eye is composed of three layers. Outer fibrous layer formed by the sclera posteriorly and the cornea anteriorly. Inner layer , sensory retina with vision concentrated at the fovea which is lateral to the optic nerve and directly posterior to the lens. In between these vascular layer – the uvea or choroid –which supplies the retina. The iris is the outer continuation of the vascular layer Lens sits just behind iris, suspended from the ciliary body. No lymphatic drainage
  • Retinoblastoma Mid 18th century: 1st clinical report of RB was recognized 1920-“ Vernoff” coined the term retinoblastoma 2.5-4% of paediatric malignancies Most common intraocular malignancy of childhood 2nd most common primary intraocular malignancy in any age group Tumor is of neuroepithelial origin & arises from unidentified progenitor cell in nucleated layers of one or both eyes Accounts for 1:17,000-34,000 live births worldwide
  • Epidemiology Slight male preponderance 1.15:1.0 More than 90% of cases occur before age of 5 year Most common among blacks & Africans Age: average age in hereditary cases: 12-14 months, sporadic cases 24-30 months Unilateral: 65-80% Bilateral: 20-35% Aetiology: unknown
  • Genetics Deletion of long arm of chromosome 13, 13q14, which is a tumor suppressor gene termed as RB gene. ‘Alfred Knudson’ hypothesis: 2 types Hereditary Non-hereditary Familial Sporadic Germline mutations 2 hits Bilateral, multifocal Unilateral, unifocal Young age older age
  • Clinical features Family history: 10% Leukocoria (white pupillary reflex): 50% , commonest Strabismus [esotropia]: 20% Ocular inflammation: due to necrosis of tumor or tumor cells may enter AC resembling hyphema [pseudohypopyon] Secondary glaucoma: angle-closure Loss of vision Proptosis: extra ocular invasion Trilateral retinoblastoma; bil RB+ pineoblastoma Distant metastases
  • Routes of spread Local spread; anteriorly- seeding of vitreous & aqueous; posteriorly, sub retinal space and choroids May spread through optic nerve Along the central retinal vessels: tumor cells pass through the lamina cribrosa and enter subarachnoid space Distant metastases: CNS, skull, bones, lymph nodes, spinal cord, bone marrow Orbital involvement
  • Staging
  • Reese-Ellsworth Classification
  • International Classification of RetinoblastomaGroup Features A Small tumor: ≤3 mm B Large tumor: >3 mm Macular: ≤3 mm to foveola Juxtapapillary: ≤1.5 mm to disc Subretinal fluid: ≤3 mm from the margin C Focal seeds Subretinal seeds: ≤3 mm Vitreous seeds: ≤3 mm Both subretinal and vitreous seeds: ≤3 mm D Diffused seeds Subretinal seeds: >3 mm Vitreous seeds: >3 mm Both subretinal and vitreous seeds: >3 mm E Extensive retinoblastoma occupying more than 50% or neovascular glaucoma or opaque media from hemorrhage in anterior chamber, vitreous or subretinal space Invasion of postlaminar optic nerve, choroid (> 2mm), sclera, orbit, anterior chamber
  • AJCC Tumour Staging System for RBT1/p1 <25% of retinaT2/pT2 >25 to 50% of retinaT3/Pt3 >50% of retina and/or intraocular beyond retinaT3a/pT3a >50% of retina and/or cells in vitreousT3b Optic diskpT3b Optic nerve up to lamina cribrosaT3c Anterior chamber and/or uveapT3c Anterior chamber and/or uvea and/or intrascleralT4/pT4 ExtraocularT4a Optic nervepT4a Beyond lamina cribrosa, not at resection lineT4b Other extraocularpT4b Other extraocular and/or at resection lineN1/pN1 RegionalMI Distant metastases
  • St. Jude’s Tumor Staging SystemStage I: Tumor (unifocal or multifocal) confined to retina a. Occupying one quadrant or less b. Occupying two quadrants or less c. Occupying more than 50% of retinal surfaceStage II: Tumor (unifocal or multifocal) confined to globe a. With vitreous seeding b. Extending to optic nerve head c. Extending to choroid d. Extending to choroid and optic nerve head e. Extending to emissariesStage III: Extraocular extension of tumor a. Extending beyond cut end of optic nerve (including subarachnoid extension) b. Extending through sclera into orbital contents c. Extending to choroid and beyond cut end of optic nerve (including subarachnoid extension) d. Extending through sclera into orbital contents and beyond cut end of optic nerve (including subarachnoid extension)Stage IV: Distant metastases a. Extending through optic nerve to brain b. Blood-borne metastases to soft tissue(s) and bone(s) c. Bone marrow metastases
  • Diagnostic workup Diagnosis of retinoblastoma is made without pathologic confirmation and is based on a clinical examination. Clinical history Physical examination: EUA  Direct ophthalmoscopy: white reflex  Indirect ophthalmoscopy:  RB seen as projecting into vitreous, creamy white in color, neovascularisation seen on surface, calcification gives cottage cheese appearance (glistening white)  RB diagnosed owing to vitreous hemorrhage, RD, severe inflammatory reaction (A) A fundus photograph of an eye with retinoblastoma (B) The corresponding sketch of the disease in the eye diagram.
  • Ophthalmic USG: Non-invasive, safe, repeatable, and immediately interpretable. B-scan USG reveals a 2D cross-sectional view, confirms presence and the relationship, the size and shape of the tumors. Orbital involvement, optic nerve invasion can be seen, extrascleral extension, and calcification.. B-scan of an eye with retinoblastoma
  • CT scan, dense heterogenous lesion with hyper dense foci corresponding to calcification. for assessing extraocular extension and invasion of the optic nerve. A computed tomography scan of a large calcified retinoblastoma in the right eye.
  • MRI Instead, as part of an extent-of-disease work-up, MRI is routinely performed. Involvement of the optic nerve, extraocular extension, and intracranial midline neoplasm in trilateral retinoblastoma are best detected. Used in differentiating retinoblastoma from simulating lesions.
  • Other tests Anterior chamber para-centesis: to assay LDH. Elevated ratio of aqueous LDH5/LDH1 iso-enzymes, elevated ratio of aqueous LDH/ serum LDH Fluorescein angiography: tumor blush CSF cytology Bone marrow biopsy &aspiration Bone scan Lab tests: Hemogram, Blood chemistries, KFT, LFT
  • Treatment of Retinoblastoma Primary goal  to ensure the survival of children.  retention of eyes and vision.  Avoidance of side effects- second malignancies, facial bony deformities, or other physical changes that can affect functional well-being. Treatment approaches are guided by the presence of intraocular or extraocular disease. 5 yr. DFS > 90% for intraocular disease pts., but < 10% for extra-ocular disease.
  • Treatment Modalities
  • Surgery
  • Enucleation Procedure: removal of globe after severing the rectus muscles, optic nerve is cut (10-20mm) near its exit from the socket Indications:  Unilateral RB with blind eye  Bilateral RB with both eyes blind- bilateral enucleation  Uni/bilateral RB with glaucoma (rubeosis iridis) with visual loss  Local recurrence after conservative measures fail  bilateral retinoblastoma in which the previously mentioned conditions exist in only one eye  a tumor present in the anterior chamber  retinoblastoma unresponsive to other forms of local therapy  cases with permanent vision loss in which intraocular tumor is suspected.
  • Exenteration Procedure: removal of globe, extra ocular muscles, lids , nerves and orbital fat Indications:  Extensive local tumor breaching the globe  Recurrence of tumor in socket after enucleation
  • Local therapies Used for small tumors < 3 – 6 mm Usually in patients with bi-lateral disease and In combination with Chemo- Radiation.
  • CryotherapyProcedure: tumor is localized (by indirect ophthalmoscope), indented trans- sclerally with nitrous oxide cryoprobe, freeze is applied (-80°c),Indications: Small tumor anterior to equator (4-7 mm in size) Small recurrence or tumor persisting after radiotherapy In conjunction with chemotherapy (may increase the intravitreal penetration of carboplatin)Side effects: Can induce acute retinal edema Accumulation of sub retinal fluid → retinal detachment
  • PhotocoagulationProcedure: obliteration of retinal vessels by creating retinal burn with laser beamIndications: Tumor ≤4.5mm at base and ≤2.5mm thick Away from macula or disc Small tumor recurrence after prior irradiation Contraindication: vitreous seeding Laser hyperthermiaProcedure: generated by Diode laser (810 nm) on continuous mode Single spot 0.8-2 mm placed on center of tumor Tumor is heated for 10-30 min per session. Central tumor temperature 460c and decreases by 20c for each mm outside the temperature spot
  • Radioactive plaque application Isotopes used: Co-60, Ir-192, I-125, 106Rh (ß emitter)  Co-60: circular, crescentic to fit around optic nerve  I-125: seeds glued within a carrier and gold shield, circular or notched configuration Procedure: 1st USG of eye done: for tumor dimensions: maximum basal diameter, max height → surgical exploration → applicators are applied over sclera overlying the tumor → 1.5-2 mm margin on either side of basal diameter → retention sutures → Rx → Re-exploration for removal of plaques
  •  Indications:  Solitary lesion 2-16 mm basal diameter  Unifocal lesions  Located greater than 3 mm from optic nerve or fovea  Thickness <10 mm  Two lesions, small or close enough to be covered by one plaque  Local recurrence (small) following radiotherapy [EBRT] Iodine 125 plaques
  • Cont…
  • Radiotherapy
  • External beam radiotherapy Indications  Multi-focal retinoblastoma  RB close to macula or optic nerve  Large tumor with vitreous seeding Positioning  Proper immobilization is important  thermoplastic or Perspex shell with the patient supine and the chin in a neutral position  Treatment is done under anesthesia: Ketamine Energy: Co-60 or 4-6 MV photons
  • Technique Lateral field technique Started in 1930’s D – shaped lateral field with anterior border kept at bony orbit Disadvantage: tumor recurrence at or near ora serrataModified lateral beam technique Two lateral opposed D-shaped fields are used
  • Direct anterior field [Hungerford et al ] Whole eye is treated Disadvantage:  Cataract formation  Dose exits through brain  Lacrimal gland irradiation-impaired tear production Advantages:  Simple, easy to setup  Reproducible  Homogenously irradiates entire retina Anterior lens sparing technique (ALD) [Abramson et al ] Lateral D-shaped field: Day1-Day 4 by photons Anterior electron beam field with central circular contact lens as lens shaped shield: on Day 5
  •  Unilateral disease:  one lateral field or  2 oblique portals [superior and inferior] Bilateral disease:  parallel opposed lateral fields The anterior beam edge is placed at the bony canthus and the beam is angled 1.5 degrees posteriorly if the contralateral eye remains in place.
  • Dose Ideal: 40-45 Gy, 1.8-2 Gy per fraction, 5 days a week For large tumor /vitreous seeding: 48-50 Gy Palliative radiotherapy:  Extra-ocular involvement: 20-25 Gy  Metastatic disease: CNS, bones: 5 Gy/1#, 15 Gy/3# Unilateral : single lateral field With anterior extension: anterior field + lateral field tilted 5-15° posteriorly Bilateral disease: parallel opposed lateral fields
  • 3D conformal radiotherapy technique based on 3D CT scan planning In unilateral RB, 4 non-coplanar fields are used. fields are anterior oblique: superior, inferior, medial, and lateral. 0.5-cm bolus can be used. entire retina should be treated, including 5 to 8 mm of the proximal optic nerve. critical structures such as the opposite eye, optic chiasm, pituitary gland, brainstem, posteriormost upper teeth, and upper cervical spine. the tumor volume is treated to the 98% or 95% line,with the aforementioned organs and tissues receiving significantly less dose.
  •  bilateral disease, six noncoplanar fields are used:  two lateral opposing, and  two anterior oblique fields to each eye following the same criteria described previously.3D CT scan reconstruction image showing beam arrangement for unilateral RB : anterior medial and lateral fields(A), anterior superior and inferior fields (B), sagittal view of composite isodose distribution (C), and axialtransverse view of isodose distribution (D)
  • Side effects of RT Cataract formation: lens Lacrimal gland: decreased tear film production Vascular: retinal vasculitis → hemorrhage, and vitreous opacity Bone & soft tissue: temporal bone hypoplasia, molar tooth abnormalities Mid-facial hypoplasia: hypotelorism, enophthalmos, atrophy of temporalis muscle, narrow and deep orbits, depressed nasion. Second malignancies: overall incidence: 3-5%  Most common are osteosarcoma, fibrosarcoma, other spindle cell sarcomas
  • Chemotherapy
  •  “Chemoreduction” (using chemotherapy to reduce the size of tumors)  area of active clinical and basic science research,  avoid enucleation and external beam radiation Indications  for patients who have visual potential in eyes containing tumors that are too large to treat with focal methods.  In patient with extra-ocular disease  Subgroup of patient with introcular disease with high risk histologic features.  Patient with bilateral disease in conjunction with Aggressive local therapy. Currently, six cycles of vincristine, carboplatin and etoposide are employed as the standard starting regimen.
  • Treatment recommendations
  • Follow up 1st 6 months: 4-6 week intervals Upto 3 years: at 4-6 month intervals Later, yearly Family history positive: all family members [other children at birth] should be examined yearly